Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy

Molecular Biology Reports

Volumn 41, Issue 5, 2014, Pages 3339-3347

  Tang, Li Qin ^a   Liu, Sheng ^a   Zhang, Shan Tang ^a   Zhu, Ling Na ^a   Wang, Feng Ling ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Second People's Hospital of Hefei   (China)

Author keywords

Berberine; Diabetic nephropathy; E prostanoid receptors

Indexed keywords

BERBERINE; INTERLEUKIN 6; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2;

ANIMAL; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY CORTEX; MALE; METABOLISM; MULTIGENE FAMILY; PATHOLOGY; RAT;

ANIMALS; BERBERINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DINOPROSTONE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INTERLEUKIN-6; KIDNEY CORTEX; MALE; MULTIGENE FAMILY; RATS; RECEPTORS, PROSTAGLANDIN E;

EID: 84905712345     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3196-4     Document Type: Article

References (59)

1. Wang FL, Tang LQ, Yang F et al (2013) Protective effects of berberine on renal function and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Rep 40:2405-2418
2. Broumand B (2007) Diabetes: changing the fate of diabetics in the dialysis unit. Blood Purif 25:39-47
3. Jefferson JA, Shankland SJ, Pichler RH (2008) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74:22-36 (Pubitemid 351841893)
4. Srinivasan K, Viswanad B, Asrat L et al (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313-320 (Pubitemid 41175991)
5. Zhou J, Zhou S, Tang J et al (2009) Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol 606:262-268
6. Breyer MD, Jacobson HR, Breyer RM (1996) Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 7:8-17 (Pubitemid 26068447)
7. Breyer MD, Breyer RM (2000) Prostaglandin E receptors and the kidney. Am J Physiol Ren Physiol 279:F12-F23 (Pubitemid 30619543)
8. DeRubertis FR, Craven PA (1995) Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am J Kidney Dis 22:727-735
9. Barnett AH (2005) Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalapril (DETAIL) study. Acta Diabetol 42(Suppl 1):S42-S49
10. Hatae N, Sugimoto Y, Ichikawa A (2002) Prostaglandin receptors: advances in the study of EP3 receptor signaling. J Biochem 131(6):781-784 (Pubitemid 34717580)
11. Boie Y, Stocco R, Sawyer N et al (1997) Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 340:227-241 (Pubitemid 28022647)
12. Jensen BL, Mann B, Skott O et al (1999) Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. Kidney Int 56:528-537 (Pubitemid 29353151)
13. Morath R, Klein T, Seyberth HW, Nusing RM (1999) Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol 10:1851-1860 (Pubitemid 29402505)
14. Sugimoto Y, Namba T, Shigemoto R et al (1994) Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. Am J Physiol Ren Physiol 35:F823-F828
15. Yin J, Gao Z, Liu D et al (2008) Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 294:E148-E156
16. Singh J, Kakkar P (2009) Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. J Ethnopharmacol 123:22-26
17. Brusq JM, Ancellin N, Grondin P (2006) Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47:1281-1288 (Pubitemid 43830720)
18. Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57:712-717 (Pubitemid 351608234)
19. Wang Y, Champbell T, Perry B (2011) Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism 60(2):298-305
20. Kang SW, Adler SG, Lapage J et al (2001) p38MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int 60:543-552 (Pubitemid 32678898)
21. Marinova EK, Nikolova DB, Popova DN et al (2000) Suppression of experimental autoimmune tubulointerstitial nephritis in BALB/c mice by berberine. Immunopharmacology 48:9-16 (Pubitemid 30259138)
22. Liu WH, Hei ZQ, Nie H et al (2008) Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J 121:706-712
23. Tang LQ, Lv F, Liu S et al (2011) Effect of berberine on expression of transforming growth factor-β1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy. Chin J Chin Mater Med 36:3494-3497
24. Tang LQ, Wang FL, Zhu LN et al (2013) Berberine ameliorates renal injury by regulating G proteins - AC - cAMP signaling in diabetic rats with nephropathy. Mol Biol Rep 40(6):3913-3923
25. Liu S, Tang LQ, Chen LM (2004) Study on extraction technology of berberine from Rhizoma coptidis by the method of orthogonaltest optimization. China Pharm 15:18-20
26. Tesch GH, Allen TJ (2007) Rodent models of streptozotocin induced diabetic nephropathy. Nephrology (Carlton) 12:261-266 (Pubitemid 46718209)
27. Zhang JT (1998) Modern experimental methods in pharmacology. Beijing Medical University, Beijing, p 982
28. Molitch ME, DeFronzo RA, Franzetal MJ (2004) Nephropathy in diabetes. Diabetes Care 27(1):S79-S83
29. Sahin K, Onderci M, Tuzcu M et al (2007) Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metabolism 56:1233-1240 (Pubitemid 47225177)
30. Yang F, Tang LQ, Wang FL et al (2011) Study of the influential factor on the establishment of experimental diabetic nephropathy in rats. Anhui Med Pharm J 16(6):735-738
31. Lee YS, Kim WS, Kim KH et al (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55:2256-2264 (Pubitemid 44743622)
32. Tang LQ, Wei W, Chen LM et al (2006) Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 108:109-115 (Pubitemid 44498992)
33. Tuttle KR (2005) Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 16:1537-1538
34. Mora C, Navarro JF (2006) Inflammation and diabetic nephropathy. Curr Diabetes Rep 6:463-468 (Pubitemid 44896406)
35. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444(7121):860-867
36. Galkina E, Ley K (2006) Leukocyte recruitment and vascular injury in diabetic nephropa-thy. J Am Soc Nephrol 17:368-377
37. Chow F, Ozols E, Nikolic-Paterson DJ et al (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65:116-128 (Pubitemid 38037496)
38. Wong CK, Szeto CC, Chan MH et al (2005) Elevation of proinflammatory cytokines, C-reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. Immunol Invest 36:47-57 (Pubitemid 46024915)
39. Navarro JF, Mora C, Gómez M et al (2008) Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-α and interleukin-6 in type 2 diabetic patients. Nephrol Dial Transpl 23(3):919-926 (Pubitemid 351767554)
40. Fernandez-Real JM, Broch M, Vendrell J et al (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520 (Pubitemid 30131802)
41. Pickup JC, Chusney GD, Thomas SM et al (2000) Plasma interleukin-6, tumour necrosis factor a and blood cytokine production in type 2 diabetes. Life Sci 67(3):291-300 (Pubitemid 30413937)
42. Kern PA, Ranganathan S, Li C et al (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280(5):E745-E751
43. Lyngso D, Simonsen L, Bulow J (2002) Interleukin-6 pro-duction in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 543:373-378 (Pubitemid 34947322)
44. Morcos M, Schlotterer A, Sayed AA (2008) Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappa B activation in cultured human proximal tubular epithelial cells. Horm Metab Res 40(11):752-759
45. Breyer MD, Breyer RM (2008) Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 9:23-29
46. Ishibashi R, Tanaka I, Kotani M et al (1999) Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 56:589-600 (Pubitemid 29353157)
47. Breyer MD, Jacobson HR, Breyer RM (1996) Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 7:8-17 (Pubitemid 26068447)
48. Rutkai I, Feher A, Erdei N et al (2009) Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes. Cardiovasc Res 83(1):148-154
49. 2 actions in the microcirculation of the rat kidney. Am J Physiol Ren Physiol 279:F755-F764
50. Kelly DJ, Zhang Y, Moe G et al (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50:2398-2404 (Pubitemid 47512400)
51. 2 in acute and chronic kidney failure. Kidney Int 70:1099-1106
52. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K et al (1999) Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 5:217-220 (Pubitemid 29068530)
53. Oliver JA (2009) Receptor-mediated actions of renin and prorenin. Kidney Int 69:13-15
54. Nasrallah R, Xiong H, Hebert RL (2007) Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2 Akita type I-diabetic mice. Am J Physiol Ren Physiol 292:F278-F284 (Pubitemid 46105267)
55. Vukicevic S, Simic P, Borovecki F et al (2008) Role of EP2 and EP4 receptor-selective agonists of prostaglandin E2 in acute and chronic kidney failure. Kidney Int 70:1099-1106 (Pubitemid 44344080)
56. Makino H, Tanaka I, Mukoyama M et al (2002) Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 13:1757-1765 (Pubitemid 34700600)
57. Faour WH, Gomi K, Kennedy CR (2008) PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism. Cell Signal 20:2156-2164
58. Stitt-Cavanagh EM, Faour WH, Takami K et al (2010) A maladaptive role for EP4 receptors in podocytes. Am Soc Nephrol 21:1678-1690
59. Makino H, Tanaka I, Mukoyama M et al (2007) Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 13:1757-1765